AI Discovers BRP Molecule That Suppresses Appetite and Promotes Fat Loss

Discovery of the BRP Molecule

According to НВ — Техно: Researchers at Stanford University have identified a molecule called BRP that significantly reduces appetite and encourages fat loss in animal studies. This breakthrough could lead to the development of a new weight loss drug with fewer side effects than Ozempic. The findings were published in the journal Nature and reported by ScienceDaily.

The BRP molecule was uncovered using artificial intelligence. The Peptide Predictor algorithm sifted through around 20,000 human genes, narrowing the search to 373 proteins potentially capable of producing active molecules. From these, 100 peptides were selected for lab testing. Notably, one 12-amino acid peptide boosted nerve cell activity by tenfold compared to controls, whereas semaglutide-the active ingredient in Ozempic-only tripled activity. The molecule was named BRP after the protein BRINP2.

Experimental Findings

In experiments, BRP reduced food intake by 50% in mice and miniature pigs within an hour of administration. Obese mice treated with BRP daily for two weeks lost an average of 3 grams, while untreated mice gained approximately the same amount. Importantly, the weight loss was due to fat reduction rather than muscle loss. Additionally, BRP improved glucose and insulin tolerance in the treated animals.

BRP operates by targeting brain regions that regulate hunger and metabolism, influencing energy expenditure. Unlike Ozempic, which slows digestion and can cause nausea and constipation, BRP primarily affects the hypothalamus. During trials, no significant changes were observed in the animals' mobility, water consumption, anxiety-related behavior, or bowel movements compared to controls.

Despite these promising results, BRP remains an experimental molecule with unknown safety, dosing parameters, and side effects in humans. Clinical trials to assess its safety in people have yet to begin. Future research will focus on identifying the receptors BRP interacts with and extending its activity duration in the body. Because peptides degrade quickly, BRP-based treatments may require frequent injections. Catherine Svensson and Laetitia Coassolo founded a company dedicated to advancing BRP development and preparing for human trials, hopeful it will prove both safe and effective.

The discovery of BRP offers exciting new possibilities for obesity treatment and appetite control, potentially providing patients with more effective and better-tolerated weight loss options. However, since BRP is still in the early stages of research, further studies are essential to fully understand its risks and benefits in humans. Upcoming clinical trials will be critical for determining its therapeutic potential.

While the discovery of the BRP molecule offers a promising avenue for weight loss with fewer side effects, it’s crucial to consider the broader implications of appetite regulation in the context of other treatments. Recent findings on unexpected side effects of unregulated retatrutide highlight the complexities of appetite control, including potential appetite surges and sleep disturbances. Understanding these dynamics can provide valuable insights into the future of weight management therapies.